Eva Nievergall

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: June 11, 2022

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Journal: Nature

Published: August 02, 2019

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Journal: Nature

Published: June 19, 2018

Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data.

Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data.

Journal: Molecular genetics and genomics : MGG

Published: October 27, 2017

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Journal: Haematologica

Published: September 23, 2017

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

Journal: Bone marrow transplantation

Published: May 17, 2016

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Journal: Leukemia

Published: September 14, 2015

PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling.

PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling.

Journal: Journal of cell science

Published: May 25, 2015

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Journal: Leukemia

Published: September 03, 2014

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Journal: Blood

Published: December 24, 2013

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Journal: Leukemia

Published: November 27, 2013

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Journal: Haematologica

Published: October 16, 2012

Showing 1-12 of 15

Last Updated: 09/26/2026